Real-world treatment patterns and visual outcomes of faricimab in patients with neovascular age-related macular degeneration in the UK at 12 months: the FARWIDE-nAMD study | Synapse
March 13, 2026Open Access
Real-world treatment patterns and visual outcomes of faricimab in patients with neovascular age-related macular degeneration in the UK at 12 months: the FARWIDE-nAMD study
Key Points
The aim is to evaluate the real-world effectiveness and safety of faricimab for treating neovascular age-related macular degeneration (nAMD).
Analyzed 1-year data from patients treated with faricimab
Evaluated visual outcomes and treatment patterns
Assessed safety profiles of the intervention
Faricimab showed significant effectiveness in improving visual outcomes at 12 months
Treatment demonstrated durability over the year
Safety profile was consistent with existing data on faricimab
Abstract
These 1-year data support real-world faricimab effectiveness, durability, and safety in nAMD.